Engineer 2
Vaxcyte
Engineer 2
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
Vaxcyte is seeking a highly motivated and technically proficient Engineer II to join the Conjugation Process Development and Manufacturing group within the CMC organization. This individual will contribute to the development, scale up, and manufacturing of Vaxcyte’s multi valent polysaccharide based conjugate vaccines, which leverage a novel carrier protein produced through cell free synthesis. Conjugation—the covalent linkage of polysaccharide antigens to carrier proteins—is a critical component of Vaxcyte’s vaccine platform, and this role will support both laboratory development and cGMP manufacturing activities.
The successful candidate will bring hands on laboratory experience, a solid understanding of bioprocess operations, and practical exposure to cGMP environments, ideally within late-stage development. This position requires close collaboration with cross functional CMC teams, active participation in production campaigns, and the ability to independently execute development experiments and document technical findings. The role offers a unique opportunity to contribute directly to the advancement of Vaxcyte’s vaccine programs while developing deep expertise in conjugation process development and manufacturing.
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte